Ratings Thermo Fisher Scientific Inc. Borsa Italiana

Equities

4TMO

US8835561023

End-of-day quote Borsa Italiana Other stock markets 18:00:00 2024-06-05 EDT			5-day change	1st Jan Change
530.8 ^EUR	+0.76%		+2.12%	+10.15%

06-05	Thermo Fisher Scientific Insider Sold Shares Worth $11,374,358, According to a Recent SEC Filing	MT
06-03	Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research	CI

Strengths

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's high margin levels account for strong profits.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.49 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
THERMO FISHER SCIENTIFIC INC.	+10.15%	222B	-
DANAHER CORPORATION	+13.72%	195B	B-
INTUITIVE SURGICAL, INC.	+23.79%	148B	B-
BOSTON SCIENTIFIC CORPORATION	+33.39%	113B	A-
SIEMENS HEALTHINEERS AG	+4.75%	66.45B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.59%	53.11B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.16%	50.03B	B+
AGILENT TECHNOLOGIES, INC.	-4.35%	38.8B	A
GE HEALTHCARE TECHNOLOGIES INC.	-1.27%	34.85B	-
RESMED, INC.	+22.61%	30.98B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes